1. Home
  2. LSTA vs LNAI Comparison

LSTA vs LNAI Comparison

Compare LSTA & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lisata Therapeutics Inc.

LSTA

Lisata Therapeutics Inc.

HOLD

Current Price

$2.05

Market Cap

20.9M

Sector

Health Care

ML Signal

HOLD

Logo Lunai Bioworks Inc. Common Stock

LNAI

Lunai Bioworks Inc. Common Stock

N/A

Current Price

$1.19

Market Cap

23.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LSTA
LNAI
Founded
1980
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Misc Health and Biotechnology Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.9M
23.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LSTA
LNAI
Price
$2.05
$1.19
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$23.50
N/A
AVG Volume (30 Days)
139.2K
11.7M
Earning Date
11-06-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,070,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.81
$0.81
52 Week High
$4.20
$21.00

Technical Indicators

Market Signals
Indicator
LSTA
LNAI
Relative Strength Index (RSI) 40.79 N/A
Support Level $1.86 N/A
Resistance Level $2.13 N/A
Average True Range (ATR) 0.16 0.00
MACD -0.00 0.00
Stochastic Oscillator 53.76 0.00

Price Performance

Historical Comparison
LSTA
LNAI

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.

About LNAI Lunai Bioworks Inc. Common Stock

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: